Fact-checked by Grok 2 weeks ago

Postcoital bleeding

Postcoital bleeding is that occurs during or immediately after in women of reproductive age. It has a prevalence ranging from 0.7% to 9% among menstruating women, making it a relatively common gynecological complaint. The condition arises from mechanical trauma to friable tissues in the genital tract, often linked to benign causes such as , polyps, atrophy, or infections like . Less frequently, it signals premalignant or malignant processes, including or invasive , with empirical data indicating that 0.6% to 1.7% of cases may involve such pathology. Although the absolute risk of malignancy remains low—estimated at approximately 1 in 220 women presenting with the symptom—prompt investigation is essential to identify treatable causes and exclude cancer, typically involving speculum examination, , and referral for persistent episodes.

Definition and Pathophysiology

Definition

Postcoital bleeding refers to vaginal spotting or bleeding that occurs during or immediately after and is unrelated to . This distinguishes it from , which arises independently of coitus, or menstrual irregularities tied to the ovarian cycle. The bleeding typically originates from the genital tract, including the , , or upper structures such as the or fallopian tubes, due to mechanical or underlying mucosal fragility during penetration. As a presenting symptom rather than a distinct disease entity, postcoital bleeding signals potential disruptions in the integrity of reproductive tract tissues, warranting evaluation to identify causative pathology. It manifests in women across reproductive ages as well as postmenopausal individuals, where atrophic changes may exacerbate vulnerability. Community-based studies report point prevalence ranging from 0.7% to 9%, reflecting variability in self-reporting and demographic factors without implying uniform risk distribution.

Pathophysiological Mechanisms

Postcoital bleeding arises primarily from mechanical disruption of the vaginal or mucosa during , where frictional forces exceed the structural integrity of the epithelium, resulting in rupture of underlying capillaries. In healthy , the provides a robust barrier against such , but when compromised, even moderate leads to hemorrhage from exposed submucosal vessels. This process is exacerbated by reduced or increased vulnerability, lowering the threshold for vascular injury. Hormonal influences, particularly estrogen deficiency, contribute by inducing epithelial , characterized by thinning of the vaginal walls and loss of glycogen-rich superficial cells, which diminishes mucosal resilience and vascular support. Postmenopausal women experience this atrophy due to , rendering the tissue pale, dry, and friable, such that intercourse-induced readily tears the attenuated layers and disrupts fragile capillaries. Empirical observations confirm that up to 40% of such women exhibit symptoms tied to this , with local estrogen restoration reversing the friability. Inflammatory states heighten and epithelial fragility through cytokine-mediated and leukocyte infiltration, creating a milieu where minor mechanical insult provokes from dilated, leaky vessels. Similarly, neoplastic processes erode architecture via invasive growth, exposing and destabilizing submucosal vasculature, which then bleeds persistently upon contact ; studies attribute 3-5% of cases to such invasive disruption in malignancies. These mechanisms underscore a causal chain from compromise to hemorrhage, independent of psychological factors.

Etiology

Benign and Infectious Causes

Infectious causes of postcoital bleeding primarily involve sexually transmitted infections (STIs) that induce , leading to mucosal inflammation and that disrupts during intercourse. is the most common bacterial pathogen associated with this presentation, accounting for a significant proportion of cases in reproductive-age women, as it erodes the epithelium and promotes vascular fragility. () similarly causes purulent with endothelial damage, resulting in spotting or frank bleeding postcoitally, often co-occurring with chlamydia in up to 40% of STI-positive individuals. , a protozoal , contributes through vaginitis and cervical erosion, with studies linking it to increased in symptomatic patients. These infections' causal role stems from direct microbial invasion and immune-mediated tissue breakdown, rendering the mucosa prone to mechanical trauma. Benign structural abnormalities, such as (eversion of the glandular epithelium), frequently underlie postcoital bleeding in premenopausal women, particularly those using combined oral contraceptives, where prevalence reaches 17-50% due to estrogen-driven columnar cell exposure. This condition affects 5-25% of women with experiencing bleeding from easily disrupted superficial vessels during coitus. polyps, benign vascular outgrowths influenced by hormonal factors and chronic irritation, cause intermittent bleeding in affected individuals, with postcoital spotting reported as a hallmark symptom from polyp avulsion or vessel rupture. Traumatic microabrasions from itself can exacerbate these, especially in the presence of inadequate , though such cases are self-limited absent underlying . In postmenopausal women, atrophic changes due to deficiency lead to vaginal and thinning, with prevalence of symptomatic genitourinary of estimated at 10-40%, manifesting as postcoital bleeding from mucosal fragility and dryness-induced friction. This hypoestrogenic state causally reduces epithelial and vascular integrity, heightening susceptibility to minor shear forces during penetration. Noninfectious or contact irritation may compound this, but empirical data underscore atrophy's predominance in this demographic.

Neoplastic and Other Serious Causes

Postcoital bleeding serves as a potential harbinger of cervical malignancy, where neoplastic transformation of the cervical epithelium, driven by persistent high-risk human papillomavirus (HPV) infection, results in friable tissue prone to hemorrhage upon intercourse-induced trauma. High-risk HPV types, particularly 16 and 18, account for approximately 70% of cervical cancers through integration into host DNA, disrupting tumor suppressor genes like p53 and Rb, and promoting uncontrolled proliferation. In evaluated cohorts of women with postcoital bleeding, cervical cancer prevalence ranges from 0.4% to 5.5%, with cervical intraepithelial neoplasia (CIN) detected in 6.8% to 17.8% of cases; recent studies report lower invasive cancer rates of 0.6% to 1.16%, reflecting improved screening and HPV vaccination impacts. Endometrial carcinoma, though less frequently linked to postcoital bleeding compared to intermenstrual or postmenopausal spotting, can manifest via extension or invasion causing contact hemorrhage, with rare case series noting it among invasive malignancies in up to 4% of postcoital bleeding evaluations. Vaginal cancers and genital tract lymphomas represent infrequent neoplastic contributors, often presenting with additional symptoms like discharge or ulceration that compound bleeding risk. Beyond neoplasms, serious non-malignant causes include inherited or acquired coagulopathies, such as or anticoagulant overuse, which amplify bleeding from minor cervical trauma or underlying lesions, though these are documented primarily in broader vaginal hemorrhage contexts rather than postcoital-specific data. Across studies, the overall yield of or high-grade in investigated postcoital bleeding cases underscores a 1% to 5% serious rate, necessitating targeted exclusion to mitigate progression risks despite predominant benign etiologies.

Epidemiology and Risk Factors

Prevalence and Incidence

Postcoital bleeding has a reported point prevalence ranging from 0.7% to 9% among menstruating women in community-based studies. One longitudinal assessment documented an annual cumulative incidence of approximately 6% in this demographic. Over a two-year period, the cumulative incidence has been estimated at 8% in naturally menstruating women. Prevalence appears elevated in postmenopausal women compared to premenopausal cohorts, though community-level data specific to this group remain limited and often derived from clinical referrals rather than population surveys. In high-risk subgroups, such as those with persistent symptoms or human papillomavirus positivity, occurrence rates can exceed general population figures, but exact quantifications vary by study design. Historical data from a cervical screening program in the 1960s and 1970s indicated that among women presenting with postcoital bleeding, the positive predictive value for was 1 in 220 cases. Recent systematic reviews and database updates as of 2023 affirm that these prevalence and incidence estimates have remained relatively stable, unaffected by advancements in programs.

Demographic and Behavioral Risk Factors

Postcoital bleeding is more frequent in younger women due to , where columnar epithelium evaginates onto the ectocervix, exposing fragile vessels prone to trauma during intercourse. This condition predominates during reproductive years, , and , with prevalence estimates of 17-50% and associations with higher parity. In contrast, postmenopausal women face elevated risk from vaginal atrophy, resulting from deficiency that thins vaginal and tissues, causing dryness and that leads to bleeding upon friction. Multiparity constitutes a demographic , correlating with higher incidence of polyps—a benign cause of postcoital bleeding—typically in women aged 40s-50s. Prior procedures, such as conization or loop electrosurgical excision, may contribute by inducing scarring or altered vascularity, though direct causation requires case-specific evaluation. Behaviorally, exposure to high-risk human papillomavirus (HPV) through multiple sexual partners represents the paramount modifiable factor, driving progression to or cancer, both of which manifest as postcoital bleeding; lifetime partners exceeding fivefold increase odds of persistent oncogenic HPV. Similarly, multiple partners heighten susceptibility to sexually transmitted infections like or , precipitating with mucosal erosion and bleeding. exacerbates these risks by impairing local immunity and promoting neoplastic changes, with studies linking it to doubled odds of postcoital bleeding independent of status. Immunosuppression, as in or transplant recipients, further amplifies vulnerability to infections and rapid HPV-related progression.

Clinical Presentation and Differential Diagnosis

Symptoms and Signs

Postcoital bleeding is defined as or spotting that occurs during or immediately after penetrative , unrelated to . The bleeding is characteristically fresh, bright red blood from the lower genital tract, often presenting as light spotting rather than profuse hemorrhage, though heavier flows can occur depending on the extent of local or . The symptom is frequently painless, distinguishing it from conditions involving deeper pelvic involvement, but dyspareunia is reported in approximately 15% of cases. Associated features may include abnormal vaginal discharge, such as mucopurulent or blood-tinged types, especially with infectious causes, or pelvic discomfort in select presentations. Intermenstrual bleeding commonly coexists, reported in up to 30% of women with abnormal uterine bleeding patterns that include postcoital episodes. On clinical examination, speculum visualization of the and often reveals contact bleeding upon manipulation, with friable tissue—such as easily disrupted polyps or inflamed mucosa—being a observable sign. Systemic manifestations, including fever or , are uncommon in early or benign presentations but may emerge with progressive neoplastic disease.

Differential Considerations

Non-gynecologic sources of bleeding may mimic postcoital bleeding if misidentified as vaginal in origin, though such instances are uncommon. Urethral caruncles, benign proliferative lesions at the urethral , can cause bright red or spotting that patients attribute to the vagina, particularly if noticed after due to coincidental timing or irritation. from conditions like or fissures could similarly be misconstrued, especially in cases involving anal or inadequate source differentiation, but pelvic examination readily distinguishes these by confirming the absence of genital tract pathology. Coagulopathies represent another category where underlying hemostatic defects amplify minor intercourse-related trauma into noticeable bleeding, without primary genital lesions. , the most prevalent inherited bleeding disorder, predisposes affected women to postcoital bleeding at rates exceeding those in the general population, as factor deficiencies impair clot formation following mucosal friction. or other platelet disorders may produce analogous effects, though these are rarer contributors to isolated postcoital presentations. Gynecologic conditions unrelated to contact trauma can simulate postcoital bleeding through temporal coincidence. Breakthrough bleeding from hormonal contraceptives or therapies manifests as unscheduled spotting independent of , lacking the reproducible mechanical trigger of true postcoital events. Early pregnancy complications, including implantation bleeding or subchorionic hemorrhage in threatened , may align incidentally with sexual activity but follow cyclical or implantation timelines rather than friction-induced patterns. Causal differentiation hinges on the strict temporal linkage to intercourse, with empirical data from evaluated cohorts indicating over 90% of cases trace to genital tract friability or lesions, rendering non-genital pursuits low-yield absent corroborative symptoms like dysuria or gastrointestinal complaints.

Diagnostic Approach

History and Examination

A detailed history is essential in evaluating postcoital bleeding, focusing on the onset, frequency, duration, and characteristics of the bleeding, such as whether it occurs during or immediately after intercourse, its volume (spotting versus heavy), and any associated pain, discharge, or dyspareunia. Clinicians should inquire about menstrual history, including cycle regularity, last menstrual period, and postmenopausal status, as well as sexual history encompassing number of partners, condom use, and prior sexually transmitted infections (STIs), to assess infection risks like chlamydia or gonorrhea. Additional elements include obstetric and gynecologic history, contraceptive use (e.g., intrauterine devices or hormonal methods that may cause cervical fragility), smoking status, and systemic symptoms suggestive of malignancy or coagulopathy, with red flags such as persistent or recurrent bleeding in postmenopausal women prompting urgent specialist referral. Recent guidance emphasizes thorough questioning without dismissal due to patient reluctance, as embarrassment may lead to underreporting of symptoms that require prompt evaluation. Physical examination begins with inspection of the external genitalia for trauma, lesions, or varicosities, followed by speculum examination to visualize the and for evident causes such as , polyps, erosions, , or friable/neoplastic tissue. Bimanual assesses for uterine or adnexal masses, tenderness, or enlargement, which may indicate underlying like fibroids or ovarian involvement. If suspicious features are noted—such as an irregular or visible bleeding source—immediate referral for is recommended per clinical protocols, prioritizing exclusion of or invasive carcinoma. In primary care settings, this examination helps cases, though limitations exist if or patient factors preclude full visualization.

Laboratory and Imaging Tests

Laboratory evaluation for postcoital bleeding begins with screening for sexually transmitted infections, including and , using endocervical or vaginal swabs, particularly when is suspected based on clinical findings. A or serum β-human chorionic gonadotropin test is advised to exclude pregnancy as a contributing factor. Cervical cytology via Pap smear is indicated if screening is not current, often combined with high-risk human papillomavirus (HPV) testing to assess for or neoplasia. These tests target infectious and precancerous causes, which account for a significant proportion of benign etiologies. Colposcopy with directed biopsy is recommended for persistent postcoital bleeding or abnormal cervical cytology to evaluate for or invasive cancer. Studies indicate a low prevalence of in such cases, ranging from 0.6% to 1.16%, yet universal investigation is justified by the high curability of early-detected malignancies. Transvaginal serves as a primary imaging modality to identify structural abnormalities such as endometrial polyps, fibroids, or thickened , especially in women over 40 or with risk factors like or irregular cycles. If findings are normal but suspicion persists, sonohysterography may provide further delineation of intrauterine . is warranted in women aged over 40 years, postmenopausal patients, or those with additional risks for or cancer, to sample for histological evaluation. These procedures prioritize high-yield exclusion of serious , despite the overall low diagnostic yield for in postcoital bleeding cohorts.

Management and Treatment

Initial Interventions

Upon presentation with postcoital bleeding, initial interventions focus on identifying and addressing potential infectious etiologies while expediting evaluation for . If clinical findings or patient history suggest , such as purulent discharge or high-risk sexual behavior, empiric antibiotic therapy is recommended to cover common pathogens including and , using regimens such as 100 mg orally twice daily for 7 days or 1 g orally as a single dose. Concurrently, patients should be advised to abstain from sexual activity until STI testing confirms resolution, to mitigate transmission risk and facilitate symptom assessment. Urgent referral to is indicated for all cases of postcoital bleeding to exclude premalignant or malignant cervical lesions, per UK National Institute for Health and Care Excellence (NICE) guidelines on suspected cancer recognition, typically via the two-week wait pathway. This approach avoids delays associated with , given the association of unexplained postcoital bleeding with or cancer in a subset of patients. Visible abnormalities like s or identified on speculum examination may be treated symptomatically at initial assessment, such as polyp removal or , but do not obviate the need for specialist referral if bleeding persists. Supportive care, including water-based lubricants for suspected in perimenopausal or postmenopausal women, is deferred until after speculum examination and basic investigations to prevent masking underlying pathology. Hemodynamic stabilization is rarely required, as postcoital bleeding typically presents as spotting rather than profuse hemorrhage, but and assessment are advised if volume loss is suspected.

Cause-Specific Therapies

For infectious causes such as due to or , targeted antibiotic therapy is recommended, typically involving 1 g orally as a dose for chlamydia or 500 mg intramuscularly plus 100 mg orally twice daily for 7 days for , with partner notification and treatment to prevent reinfection. Resolution of symptoms, including postcoital bleeding, occurs in over 90% of cases with appropriate antimicrobial treatment when compliance is ensured, though follow-up testing at 3 months is advised to confirm cure. Benign structural abnormalities like cervical polyps require polypectomy via or outpatient excision, which achieves symptom resolution in nearly all cases without recurrence if complete removal is confirmed histologically. For , or electrocautery ablation of the eversion is effective, with studies reporting a 72% cure rate for postcoital bleeding at 6 months post-treatment compared to 50% in untreated controls, and minimal complications such as transient . Vaginal atrophy, common in postmenopausal women, responds to low-dose topical estrogen therapy such as vaginal cream 0.01% applied twice weekly, which restores epithelial integrity and eliminates bleeding in 70-80% of patients within 12 weeks, with systemic absorption minimized compared to oral routes. Non-hormonal options like moisturizers provide partial relief but are less effective for friable tissue-related bleeding. Neoplastic causes, particularly or invasive carcinoma linked to human papillomavirus (HPV), necessitate staging via , , and imaging, followed by etiology-specific interventions: loop electrosurgical excision procedure (LEEP) for early with cure rates exceeding 90% for CIN2/3, or for invasive disease, radical , , or platinum-based (e.g., ) tailored to FIGO stage, achieving 5-year survival rates of 80-90% for stage IB but dropping to 15-20% for stage IV. Radiotherapy effectively controls bleeding in advanced cases, with response rates over 80% for palliation. Human papillomavirus vaccination (e.g., quadrivalent or nonavalent formulations) prior to exposure reduces the incidence of HPV-related neoplasia by 70-93% in vaccinated cohorts, thereby decreasing associated postcoital bleeding from precursor lesions, as evidenced by population-level declines in CIN3 rates post-vaccination implementation. For treatable benign and infectious etiologies, overall symptom resolution exceeds 80-90% with causal therapy, underscoring the value of etiology-directed management over symptomatic approaches.

Prognosis and Prevention

Outcomes and Complications

Most cases of postcoital bleeding arise from benign etiologies, such as , polyps, or infections, which carry an excellent prognosis with spontaneous resolution or simple interventions. In premenopausal women, approximately 60% resolve within six months without treatment, and 51% exhibit no recurrence at two-year follow-up. In instances indicative of premalignancy or malignancy, prognosis depends critically on early detection and staging. occurs in 6.8% to 17.8% of evaluated cases, while invasive is identified in 3% to 5.5%. Patients with postcoital bleeding and underlying frequently present at advanced stages, elevating risks of poorer outcomes compared to asymptomatic detections. For invasive overall, five-year relative reaches 91% when localized but declines to 19% with distant spread, highlighting the causal impact of diagnostic delays on progression from to metastatic disease. Untreated postcoital bleeding can precipitate complications including from cumulative blood loss, particularly if recurrent or voluminous. In infectious causes like , ascension may yield , , or . While aggregate mortality is low due to the >90% benign predominance, overlooked neoplastic cases enable tumor advancement, amplifying treatment resistance and lethality.

Preventive Measures

Vaccination against human papillomavirus (HPV) with quadrivalent or nonavalent vaccines, such as , targets oncogenic strains responsible for approximately 70% of cervical cancers, which frequently present with postcoital bleeding as an early symptom. Large-scale studies demonstrate that HPV reduces cervical precancer rates by up to 90% in vaccinated cohorts, thereby lowering the incidence of bleeding attributable to HPV-induced or . Administration is ideally before sexual debut, typically ages 9-12, though efficacy persists with catch-up vaccination up to age 45 for those at ongoing risk. Safe sexual practices causally mitigate transmission of pathogens underlying infectious or , common benign etiologies of postcoital bleeding. Consistent use during intercourse reduces and acquisition by 50-90%, pathogens that inflame tissue and provoke bleeding upon friction. Limiting lifetime sexual partners directly correlates with decreased HPV prevalence and subsequent pathology, as cumulative exposure elevates oncogenic risk in dose-dependent fashion per epidemiological data. Adherence to evidence-based cervical screening protocols enables detection and ablation of precancerous lesions before they progress to symptomatic hemorrhage. Guidelines recommend HPV testing or co-testing with cytology every 3-5 years for women aged 21-65, with for high-risk findings, averting up to 80% of invasive cancers that manifest as postcoital bleeding. In postmenopausal women, where bleeding portends higher malignancy odds (up to 10-15% association with cancer), vigilant screening continuation and prompt evaluation of new symptoms further reduce complication risks. For atrophy-related fragility in perimenopausal or postmenopausal phases, pre-intercourse application of water-based lubricants minimizes mucosal and friction-induced spotting, supported by clinical observations of reduced bleeding episodes. Caution with systemic replacement is warranted, as unopposed therapy elevates endometrial risks, potentially contributing to hemorrhagic pathologies; combined progestin regimens mitigate this when indicated.

References

  1. [1]
    Postcoital Bleeding: A Review on Etiology, Diagnosis, and ... - NIH
    The prevalence of postcoital bleeding ranges from 0.7 to 9.0 percent of menstruating women. There are multiple etiologies for this common complaint in which ...
  2. [2]
    A systematic review of postcoital bleeding and risk of cervical cancer
    The point prevalence of postcoital bleeding in the community ranged from 0.7 to 9% among women. One study reported an annual cumulative incidence of 6% of ...
  3. [3]
    Cervical Ectropion - StatPearls - NCBI Bookshelf
    May 31, 2023 · Postcoital bleeding. It is seen in 5 to 25 percent of women with cervical ectropion. The fine blood vessels in the epithelium are torn very ...Cervical Ectropion · Pathophysiology · Treatment / Management
  4. [4]
    The Incidence of Cervical Intraepithelial Neoplasia or... - LWW
    Postcoital bleeding can be related to multiple benign etiologies;1 it may be a symptom of cervical cancer, although the reported incidence is low (0.6%–1.16%).Missing: empirical | Show results with:empirical
  5. [5]
    The incidence of cervical cancer in women with postcoital bleeding ...
    Jul 30, 2022 · The positive predictive value for diagnosing cervical cancer was 1.70% for postcoital bleeding (95% confidence interval [CI] 0.64–3.7) and 0.31% ...Abstract · Methods · Results · DiscussionMissing: risk empirical
  6. [6]
    Postcoital Bleeding and Cervical Cancer Risk - AAFP
    Oct 15, 2006 · The best estimate is that approximately one out of 220 women with postcoital bleeding has invasive cervical cancer.Missing: empirical | Show results with:empirical
  7. [7]
    Postcoital bleeding: a review on etiology, diagnosis, and management
    The prevalence of postcoital bleeding ranges from 0.7 to 9.0 percent of menstruating women. There are multiple etiologies for this common complaint in which ...
  8. [8]
    Postcoital bleeding in females - UpToDate
    Sep 15, 2025 · As postcoital bleeding can be caused by gynecologic malignancy and sexually transmitted infections, in addition to numerous benign conditions, ...
  9. [9]
    Postcoital Bleeding - DynaMed
    Aug 23, 2023 · 38 studies which reported or allowed calculation of prevalence or incidence of postcoital bleeding women in the community, women in primary ...
  10. [10]
    Postcoital bleeding - PMC - NIH
    Sep 11, 2023 · Postcoital bleeding is attributable to cervical intraepithelial neoplasia and cervical cancer in 7%–18% and 3%–5% of affected patients, respectively.
  11. [11]
    Postcoital bleeding in women
    Dec 1, 2017 · The point prevalence determined in large community surveys using self-completed questionnaires ranges from 0.7 to 9 percent [3,4].
  12. [12]
    Why Are You Bleeding After Sex? - Cleveland Clinic Health Essentials
    Vaginal bleeding or spotting that occurs after intercourse is known as postcoital bleeding. ... But if there are symptoms, such as excessive discharge or bleeding ...Vaginal Atrophy Or Dryness · Cervicitis · Uterine Prolapse<|separator|>
  13. [13]
    Aetiology and management of postcoital and intermenstrual bleeding
    Benign cervical causes, Cervical ectropion (most common in younger, sexually active women), cervicitis (often chlamydia or other infections), cervical polyps ...
  14. [14]
    Cervical Ectropion - Geeky Medics
    Dec 7, 2024 · Risk factors: reproductive age, pregnancy, puberty, oral contraceptives; prevalence 17-50%, higher with parity. Symptoms: often asymptomatic ...
  15. [15]
    Cervical Polyps - StatPearls - NCBI Bookshelf
    May 29, 2025 · Most cervical polyps are asymptomatic, although some may cause abnormal vaginal bleeding, particularly after intercourse or between menstrual ...
  16. [16]
    Diagnosis and Treatment of Atrophic Vaginitis - AAFP
    May 15, 2000 · Up to 40 percent of postmenopausal women have symptoms of atrophic vaginitis. Because the condition is attributable to estrogen deficiency, ...Missing: postcoital | Show results with:postcoital
  17. [17]
    Vaginal atrophy - Symptoms & causes - Mayo Clinic
    Vaginal atrophy (atrophic vaginitis) is thinning, drying and inflammation of the vaginal walls that may occur when your body has less estrogen.
  18. [18]
    Bleeding after menopause | The Royal Women's Hospital
    Most of the time, postmenopausal bleeding is caused by: inflammation and thinning of the lining of your vagina (called atrophic vaginitis); thinning of the ...
  19. [19]
    Cervical cancer | NHS inform
    Sep 24, 2025 · Unusual bleeding. In most cases, vaginal bleeding is the first noticeable symptom of cervical cancer. It usually occurs after having sex.<|separator|>
  20. [20]
    HPV and cervical cancer: What you need to know
    Apr 16, 2020 · Symptoms of cervical cancer in women can appear years after an HPV infection. They include: Bleeding and spotting between menstrual periods.
  21. [21]
    A systematic review of postcoital bleeding and risk of cervical cancer
    In the largest English study of women with postcoital bleeding13 only 4% were diagnosed as having invasive cancer (including vaginal and endometrial).
  22. [22]
    Intermenstrual and post-coital bleeding - ScienceDirect.com
    Cervical and endometrial cancers however are associated with abnormal bleeding and therefore it is essential that women with these symptoms are evaluated ...
  23. [23]
    Post-coital bleeding: What is the incidence of significant ...
    Overall, 0.7–39% of women with cervical cancer have experienced post-coital bleeding [1]. Evidence from a case series suggests that women presenting with post- ...Missing: empirical | Show results with:empirical
  24. [24]
    Postcoital Bleeding: A Review on Etiology, Diagnosis, and ...
    Jun 17, 2014 · The prevalence of postcoital bleeding ranges from 0.7 to 9.0 percent of menstruating women. There are multiple etiologies for this common ...
  25. [25]
    Postcoital bleeding is a predictor for cervical dysplasia | PLOS One
    May 23, 2019 · Objective. To identify risk-factors for dysplasia/cancer among patients presenting post-coital bleeding (PCB). Methods. Using large health ...Missing: empirical | Show results with:empirical
  26. [26]
    Vaginal Atrophy: Causes, Symptoms, Diagnosis & Treatment
    It's a condition where the lining of your vagina gets drier and thinner from a lack of estrogen. Burning, itching, spotting and pain with sex are common ...
  27. [27]
    Evaluation of women presenting with postcoital bleeding by cytology ...
    Jan 15, 2009 · Information regarding the risk factors for cervical cancer, such as age at first intercourse, smoking, number of partners, parity, and ...Missing: demographic behavioral
  28. [28]
    Cervicitis - StatPearls - NCBI Bookshelf - NIH
    Jan 21, 2025 · Aside from age, additional risk factors include: Having a new sex partner. Having multiple sex partners. Having a sex partner who has concurrent ...
  29. [29]
    Risk factors for postcoital bleeding among women with or ... - PubMed
    These data suggest that smoking, a modifiable risk factor, may increase risk of postcoital bleeding and contribute to susceptibility for HIV and other STDs.
  30. [30]
    Postcoital bleeding - CMAJ
    Sep 11, 2023 · Postcoital bleeding is attributable to cervical intraepithelial neoplasia and cervical cancer in 7%–18% and 3%–5% of affected patients, respectively.
  31. [31]
    Urinary tract bleeding from a urethral caruncle mimicking genital ...
    Feb 25, 2019 · We present a case wherein vaginal bleeding was initially considered but was later identified to be due to a urethral caruncle.
  32. [32]
    Hematemesis, Melena, and Hematochezia - Clinical Methods - NCBI
    Hematemesis is the vomiting of blood, which may be obviously red or have an appearance similar to coffee grounds. Melena is the passage of black, tarry stools.
  33. [33]
    Sexuality and bleeding in von Willebrand disease - PubMed
    Feb 27, 2025 · Women with VWD experience more sexual restrictions than men and report more postcoital bleeding than the general population ... von Willebrand ...
  34. [34]
    Intermenstrual and Postcoital Bleeding | Doctor - Patient.info
    Postcoital bleeding (PCB) is non-menstrual bleeding that occurs immediately after sexual intercourse. Breakthrough bleeding (BTB) is irregular bleeding ...
  35. [35]
    [PDF] Post Coital Bleeding/Suspicious Cervix Guideline - WISDOM
    Postcoital Bleeding. Non menstrual bleeding that occurs during or immediately after intercourse. Investigations include: •. Pregnancy test. •. Perform cervical ...
  36. [36]
    [PDF] Investigation and management of postcoital bleeding
    Visual inspection of the cervix may identify a cervical ectopy or a polyp. 132. Most invasive cancers causing postcoital bleeding are clinically apparent on.
  37. [37]
    [PDF] Management of Postcoital Bleeding in Primary Care
    Conduct a bimanual and speculum examination and note the findings (e.g. normal, ectropion, cervicitis, cervical polyp). Refer to online resource below for ...
  38. [38]
    Investigation and management of postcoital bleeding - Owens - 2022
    Nov 24, 2021 · Postcoital bleeding is defined as nonmenstrual bleeding or spotting occurring immediately after sexual intercourse. Estimates of the prevalence ...Introduction · Assessment of women with... · Other · When is referral to colposcopy...
  39. [39]
    The incidence of cervical cancer in women with postcoital bleeding ...
    Jul 30, 2022 · Results: Of the 604 women referred, 1.16% were diagnosed with cervical cancer. None of the women who were up-to-date with cervical screening ...
  40. [40]
    Urethritis and Cervicitis - STI Treatment Guidelines - CDC
    M. genitalium might be considered for cases of cervicitis that persist after azithromycin or doxycycline therapy in which reexposure to an infected partner or ...
  41. [41]
  42. [42]
    Postcoital bleeding (criteria for urgent referral) - GP Notebook
    Mar 7, 2025 · guidelines for urgent referral:​​ any woman with clinical features (vaginal discharge, postmenopausal, postcoital and persistent intermenstrual ...
  43. [43]
  44. [44]
    [PDF] Postcoital bleeding (PCB) - NHS Sussex
    Postcoital bleeding (PCB). History – consider duration, frequency and severity of symptoms, consider contraception and sexual health hx, use of hormones eg ...
  45. [45]
    Cryotherapy as the treatment modality of postcoital bleeding
    Aug 6, 2025 · At six months, the cryotherapy group reported a cure rate of 72.1% while that in the control group the cure rate was 50.0% (P = 0.04). The ...
  46. [46]
    Vulvovaginal Atrophy - PMC - NIH
    Common symptoms include vaginal dryness, irritation, postcoital bleeding, and soreness. ... vaginal estrogen therapy on markers of postmenopausal estrogen status.
  47. [47]
    Genitourinary syndrome of menopause (vulvovaginal atrophy)
    Apr 21, 2025 · Vulvovaginal atrophy (VVA; also referred to as vaginal atrophy, urogenital atrophy, or atrophic vaginitis) results from estrogen loss and is ...
  48. [48]
    Impact of HPV Vaccination on the Incidence of High-Grade Cervical ...
    Apr 16, 2024 · Cervarix has demonstrated a remarkable 93% effectiveness in preventing cervical intraepithelial neoplasia grade 3 (CIN3) lesions, irrespective ...
  49. [49]
    Cervical Cancer Prognosis and Survival Rates - NCI
    Apr 27, 2023 · When cervical cancer is diagnosed at an early stage, the 5-year relative survival rate is 91%. When cervical cancer is diagnosed after it ...
  50. [50]
    Study Confirms HPV Vaccine Prevents Cervical Cancer - NCI
    Oct 14, 2020 · Widespread HPV vaccine use dramatically reduces the number of women who will develop cervical cancer, a large study has shown.Missing: neoplasia bleeding
  51. [51]
    HPV vaccine: Who needs it, how it works - Mayo Clinic
    The HPV vaccine protects against genital warts and most cases of cervical cancer. It protects against cancer of the vagina, vulva, penis or anus caused by HPV.
  52. [52]
    The impact of HPV vaccination beyond cancer prevention - NIH
    In this review, we examine this evidence and the possible mechanisms by which HPV vaccination may prevent these APOs. Large-scale studies linking HPV ...Missing: postcoital | Show results with:postcoital